BeStock  
Stocks › Biotechnology › DYN

Dyne Therapeutics DYN

US equityMarket cap rank #2457Biotechnology
$15.50 −$0.53 (-3.31%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $15.50 0.00%
Open$15.91
Prev close$16.03
Day range$15.41 – $16.48
Volume2.23M
Market cap$2.90B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership103.7%-12.59 pts vs. prior quarter
Institutions holding301+4 vs. prior quarter
Insider trades (recent)15 buys / 35 sellsNet selling
Short interest13.05% of floatDays to cover 10.8 · as of 30 Oct 2026
Short-sale volume share21.9%5-day average of daily volume

Short-sale volume as % of daily volume

12%22%31%41%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$12.75M (7 inflow days, 13 outflow days).

Net flow by order size, last 20 sessions

−$10.8MSuper−$1.9MBig+$2.1MMid+$574.2KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 43.0% of shares outstanding.

Largest holders

  • T. Rowe Price Group, Inc.18.60%
  • BlackRock7.72%
  • Janus Henderson Group plc6.40%
  • FMR5.95%
  • State Street Global Advisors4.35%
  • Vanguard Capital Management, LLC4.03%
  • Orbis Investment Management Limited3.74%
  • Vanguard Portfolio Management, LLC2.50%

By investor type

  • Mutual Fund69.03%
  • VC/PE Fund17.70%
  • Hedge Fund12.02%
  • Public Company3.71%
  • Government Pension Fund0.64%
  • Individual/Insider0.27%
  • Private Company0.17%
  • Insurance Company0.16%

Reported short interest has risen from 11.49% to 13.05% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
BlackRock Mutual Fund 2026/Q3 +2,067,232 7.7%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +1,241,344 4.0%
State Street Global Advisors Mutual Fund 2026/Q3 +700,047 4.4%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +652,945 2.3%
Fiera Capital Corporation Mutual Fund 2026/Q3 +645,496 0.8%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +643,239 2.5%
Morgan Stanley Public Company 2026/Q3 +424,485 0.6%
BNY Mellon Asset Management Mutual Fund 2026/Q3 +365,860 0.4%
Hartford Funds Management Company, LLC Mutual Fund 2026/Q3 +332,751 0.2%
Artal Group S.A. VC/PE Fund 2026/Q3 +300,000 1.3%
Hartford Funds Management Company, LLC Mutual Fund 2026/Q3 +311,663 0.2%
Hartford Funds Management Company, LLC Mutual Fund 2026/Q3 +250,000 0.1%
FMR Mutual Fund 2026/Q3 +2,298,020 6.0%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +1,734,919 18.6%
Marshall Wace LLP Hedge Fund 2026/Q3 +1,405,770 0.8%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
12 Nov 2026 Douglas Kerr Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -2,604 $16.82 –
12 Nov 2026 John Cox Chief Executive Officer Intent to Sell (Form 144) -5,513 $16.82 –
19 Oct 2026 Douglas Kerr Head of Research & Development and Chief Medical Officer Other Acquisition +8,000 – 133,126
19 Oct 2026 Douglas Kerr Head of Research & Development and Chief Medical Officer Other Derivative Acquisition +12,000 $16.27 12,000
1 Oct 2026 Brian Posner Independent Director Open Market Acquisition +2,500 $16.00 27,000
7 Sep 2026 Douglas Kerr Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -35 $18.89 –
7 Sep 2026 John Cox Chief Executive Officer Automatic Disposition -5,658 $18.88 190,274
7 Sep 2026 Douglas Kerr Head of Research & Development and Chief Medical Officer Automatic Disposition -5,035 $24.35 37,438
7 Sep 2026 Johanna Friedl-Naderer Chief Commercial Officer Automatic Disposition -1,085 $24.35 49,931
3 Sep 2026 Douglas Kerr Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -5,000 $24.35 –
13 Aug 2026 Atlas Venture Advisors, Inc. Automatic Disposition -2,586,928 $26.20 3,440,720
12 Aug 2026 Douglas Kerr Head of Research & Development and Chief Medical Officer Automatic Disposition -1,556 $26.28 27,598
12 Aug 2026 John Cox Chief Executive Officer Automatic Disposition -4,986 $26.28 186,851
12 Aug 2026 Erick Lucera CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer Automatic Disposition -1,797 $26.28 13,315
12 Aug 2026 Johanna Friedl-Naderer Chief Commercial Officer Automatic Disposition -226 $26.28 34,054
26 Jul 2026 Forbion Capital Partners B.V. Automatic Disposition -261,460 $26.04 3,586,796
6 Jul 2026 Atlas Venture Advisors, Inc. Open Market Disposition -5,000 $23.61 6,027,648
6 Jul 2026 Atlas Venture Advisors, Inc. Automatic Disposition -772,451 $23.62 6,027,648
28 Jun 2026 Atlas Venture Advisors, Inc. Automatic Disposition -504,695 $21.28 6,805,099
24 Jun 2026 Erick Lucera CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer Open Market Disposition -2,362 $20.37 11,050

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 24,376,615 13.1% 10.8
15 Oct 2026 25,465,761 13.6% 7.4
30 Sep 2026 25,977,390 13.9% 9.0
15 Sep 2026 23,381,047 12.5% 5.5
31 Aug 2026 20,790,669 11.1% 13.5
14 Aug 2026 21,459,799 11.5% 11.0

Discussion

No comments yet — be the first to weigh in on DYN.

Sign in to join the discussion.

Scroll to Top